BAFF promotes T cell activation through the BAFF-BAFF-R-PI3K-Akt signaling pathway - 17/05/19


pages | 10 |
Iconographies | 7 |
Vidéos | 0 |
Autres | 0 |
Highlights |
• | BAFF is able to promote the vitality and activation of T lymphocytes. |
• | BAFF promotes T lymphocyte activation through the PI3k-Akt signaling pathway mediated by BAFF-R. |
• | TACI-Fc not only inhibits the activation of B cells, but also that of T cells. |
Abstract |
B-cell activating factor from the tumor necrosis factor family (BAFF) has revealed its critical role in B cell proliferation and survival, as well as the pathogenesis of T-cell mediated autoimmune disease. However, the effect and molecular mechanisms of BAFF on T cell physiological function have not been fully elucidated. In this study it was seen that BAFF can promote the vitality of purified T cells, increase the proportion of CD3+CD4+, CD4+CD25+, CD4+CD154+, and CD4+CD69+ subgroups and reduce the proportion of CD4+CD62L+ subgroups. Negating BAFF activity with Atacicept (TACI-Fc) reverses vitality and activation of T cells. Furthermore, immunofluorescence detection revealed that BAFF promotes the expression of BAFF receptor (BAFF-R) and transmembrane activator and CAML interactor (TACI) in T cells. Flow cytometry displayed that BAFF/BAFF-R activates the PI3K-Akt signaling pathway while the application of PI3K inhibitor (wortmannin) illuminated that BAFF induces T cell vitality and activation through the PI3K-Akt signaling pathway. We conclude that BAFF is involved in not only the physiology of B cells, but also that of T cells. BAFF affects physiological T-cell activation through BAFF-R-mediated activation of the PI3K-Akt signaling pathway which mirrors one of the pathological mechanisms of T cell-mediated autoimmune diseases.
Le texte complet de cet article est disponible en PDF.Keywords : B-cell activating factor from the tumor necrosis factor family (BAFF), B-cell activating factor from the tumor necrosis factor family receptor (BAFF-R), Transmembrane activator and CAML interactor (TACI), T cell activation, Phosphoinositide 3-kinase (PI3K)
Plan
Vol 114
Article 108796- juin 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?